Piotr (Pete) E. Korzynski
Biography
Piotr (Pete) E. Korzynski is a partner in Baker McKenzie's Corporate & Securities Group in Chicago. He has experience advising clients on public and private mergers and acquisitions, equity transfers, corporate finance, SEC compliance matters and corporate governance.
Pete has previously maintained an active pro bono practice and has previously served as the Chair of the Sargent Shriver National Center on Poverty Law’s Professionals’ Council, a volunteer board supporting the organization’s national anti-poverty advocacy. He has represented the Shriver Center and asylum applicants in various US federal appellate matters, including in argument and briefing in Ferreira v. Lynch, 831 F.3d 803 (7th Cir. 2016) (clarifying that adverse credibility findings against asylum applicants may not be based on trivial inconsistencies from, or on otherwise unreliable, preliminary interviews).
Prior to joining Baker McKenzie, Pete was an attorney in the corporate practice group of a New York-based international law firm. He also previously served as an extern to the Honorable Joan B. Gottschall, judge of the US District Court for the Northern District of Illinois. While in law school, Pete served as a senior editor and articles committee member of the Stanford Law & Policy Review.
Practice Focus
Representative Legal Matters
Since joining the Firm, Pete has worked on the following representative matters:
- Represented Marel hf., a global food processing company, in its pending EUR 3.5 billion sale to John Bean Technologies Corporation.
- Represented Numab Therapeutics in its pending USD 1.25 billion sale of its "NM26" program assets related to a treatment targeting atopic dermatitis to Johnson & Johnson.
- Represented Olink Holding AB (publ), a global proteomics products and services company, in its pending USD 3.1 billion sale to Thermo Fisher Scientific.
- Represented Cummins Inc. in the global carve-out and USD 316 million IPO split-off of its filtration business through Atmus Filtration Technologies Inc.
- Represented Abbott Laboratories in its acquisitions of
- Cardiovascular Systems, Inc., a medical device company, for USD 890 million; and
- GLP systems GmbH, a lab automation company, from Sonic Healthcare and other minority shareholders.
- Represented Bayer AG in its acquisitions of
- Asklepios BioPharmaceutical, Inc., a gene therapy company, in a transaction valued at up to USD 4 billion, including potential milestone payments; and
- Vividion Therapeutics Inc., a pharmaceutical company focused on cancers and inflammatory diseases, in a transaction valued at up to USD 2 billion, including potential milestone payments.
- Represented Acorda Therapeutics, Inc., a biopharmaceutical company focused on developing therapies for neurological disorders, in its pending USD 185 million sale of substantially all of its assets to Merz Pharma GmbH & Co. KGaA through a sale process pursuant Section 363 of the United States Bankruptcy Code.
- Represented Huttig Building Products, Inc., a distributor of millwork, building materials and wood products for residential construction and in-home improvement, in its USD 350 million sale to Woodgrain, Inc.
- Represented Virtual Therapeutics Corporation in its pending acquisition of Akili, Inc., a digital medicine company.
- Represented H. Lundbeck A/S in its acquisition of Alder Biopharmaceuticals, Inc., a company focused on migraine treatment and prevention, in a transaction valued at USD 1.95 billion in cash and contingent value rights.
Admissions
- U.S. Court of Appeals, Seventh Circuit~United States (2013)
- Illinois~United States (2012)
Education
- Stanford Law School (JD, with Pro Bono Distinction, Gerald Gunther Prize for Outstanding Performance in Constitutional Law I) (2012)
- University of Chicago (BA, with general honors, Phi Beta Kappa, Lee Family Prize) (2007)
Languages
- English
- Polish